Novel drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. The novel drug delivery systems minimize drug degradation and loss, prevent harmful side-effects and increase drug bioavailability and the fraction of the drug accumulated in the required zone. A large variety of embolic agents are used by interventional radiologists for the selective occlusion of arteries supplying blood to tumors which depends on various factors including size of the vessel to be embolized, duration of the vessel to be occluded, desired clinical outcome and also the intrinsic properties and behavior of the agent.
The global novel drug delivery systems for cancer therapy market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021).
The global novel drug delivery systems for cancer therapy market segmentation is based on technology such as embolization particles – drug eluting beads, Polyvinyl Alcohol particles, microspheres, gelatin-based embolization devices, selective internal radiation therapy (SIRT/ Radioembolization), Holmium-based microspheres; Liquid Embolics – Onyx (LES and HD-500), TRUFILL nBCA LES; and nanoparticles.
The global novel drug delivery systems for cancer therapy market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global novel drug delivery systems for cancer therapy market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global novel drug delivery systems for cancer therapy market and included in this report are Advanced Medical Isotope Corporation, Bind Therapeutics, Boston Scientific Corporation, BTG plc, CeloNova BioSciences, Inc., Cook Medical, Inc., Cospheric LLC, Covidien, plc, Eckert & Ziegler BEBIG, EmboMedics, Inc., Kobo Products, Inc., Merit Medical Systems, Inc., Mo-Sci Corporation, Nanobiotix, Polysciences, Inc., Sirtex Medical, Inc. and Terumo Medical Corporation.